NREP
NEW REPRESENTATIVE AT IB RECEIVED
14/05/2026
Voltar para busca
Dado oficial do USPTO
REPHINE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
46
Atualização mais recente
15/05/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42, 45
Data de depósito
07/06/2022
Data de registro
30/04/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/04/2024
Última transação
15/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
LOZEAU, BRANDON THOMAS
Unidade examinadora
N90
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Rephine Limited
Representantes
Michael J. Brown Michael J Brown Law Office LLC
Classificação técnica
Classes Nice
Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Pharmaceutical product evaluation; quality audits in the nature of product quality evaluation; product quality control testing; product safety testing services; testing services in the field of manufacturing safety; quality assurance consultancy in the field of pharmaceuticals and the manufacture of pharmaceuticals; inspection services of pharmaceuticals and manufacturing processes for pharmaceuticals for quality control; inspection of manufacturing processes to determine conformance with certification standards for qualityreliabilitysafety; inspection of pharmaceuticals; product quality testing services; testing of pharmaceuticals; quality control for others to determine conformance with established product certification standards; product quality evaluation services in the nature of quality control for others; industrial analysis services in the field of pharmaceuticals and manufacturing processes for pharmaceuticals; testinginspectionquality controlevaluationverification and analysis of medical products and pharmaceuticals for others; testinginspectionquality controlverificationevaluation and analysis of medical products and pharmaceuticals for others for compliance with quality standards; testingquality control inspectionevaluationverification and analysis of quality management systemsmanufacturing systemsmanufacturing methods and manufacturing processes; conducting clinical trials for others; scientific research in the nature of scientific study protocol development; research and development in the pharmaceutical field; informationadvisory and consultancy services in relation to the aforesaid
Classe 45
Regulatory compliance auditing; legal compliance auditing; good manufacturing practices audit in the nature of legal compliance auditing; advisory services relating to regulatory affairs in the field of the manufacture of pharmaceuticals; reviewing standards and practices to assure compliance with manufacturing process safetyproduct safety and product packaging laws and regulations; legal and regulatory information services relating to pharmaceutical manufacturing standards; analysis of datapolicy and processprovision of advice and assistance relating to standards and practices to ensure compliance with manufacturing process safetyproduct safety and product packaging laws and regulations; legal and regulatory compliance consulting services in the field of the manufacture of pharmaceuticals; legal and regulatory advisory and consultancy services in relation to clinical trials; provision of information and advice relating to regulatory compliance systems in the field of the manufacture of pharmaceuticals; legal serviceslegal risk assessment services for the security of goods and individuals; project management consulting services relating to regulatory compliance requirements for pharmaceutical manufacturing safety and security; regulatory compliance consulting in the field of the manufacture of pharmaceuticalsprovision of benchmarking and reference information relating to pharmaceutical safety standards; informationadvisory and consultancy services in relation to the aforesaid
Publicações
Histórico de despachos e eventos da marca no USPTO.
46 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
17/11/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
26/10/2024
FIMP
FINAL DISPOSITION PROCESSED
26/10/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30/07/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
30/04/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
30/04/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
29/04/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/04/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
10/04/2024
GPNX
NOTIFICATION PROCESSED BY IB
14/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
13/02/2024
PUBO
PUBLISHED FOR OPPOSITION
13/02/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
24/01/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
24/01/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
24/01/2024
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/01/2024
ALIE
ASSIGNED TO LIE
10/01/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/11/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
22/11/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
22/11/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
22/11/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
22/11/2023
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
14/11/2023
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
03/10/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/09/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
14/09/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/09/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
14/09/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/09/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
17/07/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
17/07/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
17/07/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
17/07/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/06/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/06/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/06/2023
RFNT
REFUSAL PROCESSED BY IB
18/06/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/06/2023
RFRR
REFUSAL PROCESSED BY MPU
01/06/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/04/2023
CNRT
NON-FINAL ACTION WRITTEN
03/04/2023
DOCK
ASSIGNED TO EXAMINER
22/03/2023
MAFR
APPLICATION FILING RECEIPT MAILED
18/11/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/11/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/11/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace REPHINE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.